PV Bulletin
Health CanadaCanada

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Health Canada introduced the Ministerial Reliance Order allowing the use of foreign regulatory data in drug submissions.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Country ComplianceSignal Management
Action needed

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Draft Guidance
Policy status
Consultation
Publication date
2026-07-15
Consultation deadline
2026-09-12
Policy change
Operationalizes the Ministerial Reliance Order by describing evidentiary expectations, eligibility criteria, and manufacturer responsibilities for seeking deeming based on foreign authorizations.

Key changes

Outlines scenarios for reliance: general deeming, 120-day filing, and joint reviews. Specifies requirements for demonstrating safety comparability.

Affected workflows

Country ComplianceSignal Management

PV impact

Details the process for using foreign Risk Management Plans (RMPs) and safety data to satisfy Canadian requirements, provided the MAH justifies the applicability of foreign data to the Canadian context.

View regulator source

Source document details

Exact policy details

Regulatory requirements for filing
Complete regulatory submission must be filed in accordance with applicable filing requirements under the Food and Drug Regulations.
Applies to: Manufacturers filing human or veterinary new drug submissions, abbreviated new drug submissions, or supplements in Canada.
Source document states: 'A manufacturer must submit a complete regulatory submission in accordance with applicable filing requirements under the Food and Drug Regulations.' · p. 1 · High · Source
Conditions for deeming under the Order
The proposed Canadian drug must have the same strength, dosage form, route of administration, and medicinal ingredients as the foreign drug.
Applies to: Manufacturers seeking deeming under the Ministerial Reliance Order.
Source document states: 'Manufacturers must demonstrate that: the proposed Canadian drug has the same strength, dosage form, route of administration and medicinal ingredients as the foreign drug.' · p. 1 · High · Source

Workflow rule impacts

Country ComplianceHealth Canada review teams

Potential to simplify submissions by removing the need for certain examinations.

Inclusion of reliance on foreign regulatory authority documents.

Source document expresses intent to improve efficiency and reduce duplication in the review process. · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 15, 2026

Full briefing

What changed

Health Canada established a legal framework that allows reliance on foreign regulatory assessments for designated drug classes, making safety and efficacy requirements contingent on verified foreign data.

Why it matters

This Order enhances efficiency in drug approvals in Canada, encourages more submissions, and fosters collaboration with international regulatory bodies, potentially increasing drug availability in the Canadian market.

Practical implication

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

#Health Canada#Safety Signals#policy-change#guidance#firecrawl-policy-agent#Effective#Regulation

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicCenter for Drug Evaluation (CDE), National Medical Products Administration (NMPA) · China · Updated Jul 14, 2026

Technical Guidelines for Communication on Real-World Evidence Supporting the Extension of Pediatric Indications for Marketed Drugs (Draft for Comments)

Urgency: High

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Consultation
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Updated eCTD v4.0 technical validation criteria

Urgency: High

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Technical Guidance
Read impact briefarrow_forward
publicFood and Drug Administration · United States · Updated Jul 13, 2026

Psychedelic Drugs: Considerations for Clinical Investigations

Urgency: High

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward